Cargando…
Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics
Objective Nausea and vomiting are the most distressful side effects of cytotoxic drugs in cancer patients. Antiemetics are commonly used to reduce these side effects. However, the current antiemetic efficacy is about 70–80% in patients treated with highly-emetogenic cytotoxic drugs. One of the poten...
Autores principales: | Perwitasari, D. A., Gelderblom, Hans, Atthobari, Jarir, Mustofa, Mustofa, Dwiprahasto, Iwan, Nortier, Johan W. R., Guchelaar, Henk-Jan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042115/ https://www.ncbi.nlm.nih.gov/pubmed/21365391 http://dx.doi.org/10.1007/s11096-010-9454-1 |
Ejemplares similares
-
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009) -
The Development of Quality of Life Questionnaire for Indonesian Breast Cancer Patients: INA-BCHRQoL
por: Saptaningsih, Agusdini Banun, et al.
Publicado: (2018) -
Palonosetron as an anti-emetic and anti-nausea agent in oncology
por: Aapro, Matti S
Publicado: (2007) -
Pharmacogenetics in the clinic
por: Guchelaar, H.-J.
Publicado: (2013) -
Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
por: de Wit, R., et al.
Publicado: (1998)